The Bill and Melinda Gates Foundation offers $ 140 million to develop a tiny medical implantable pumping device that adapts to people's body and prevents them from Human Immunodeficiency Virus (HIV).
The device, which can store 6 or 12 month dosing, has been developed by a Boston-based company, Intarcia Theraputics Inc., which announced its funding from the Foundation in a press release.
The purpose of the device, which is placed under the subcutaneous tissue, is to provide a constant delivery of anti-viral drugs at regular intervals, thus removing the need for medication on a daily basis. Such applications may be beneficial in areas such as sub-Saharan Africa, where HIV is a very serious threat. It implements one technique virus prevention known as PrEP (pre-exposure prophylaxis), which is an attempt to treat potential patients before being diagnosed with HIV.
Intarcia also created a version of the device for the treatment of 2 type diabetes. In the case of HIV, Intarcia is still trying to figure out which drug should be placed in the mini-pump that has match size.
An HIV-infected person develops AIDS (Acquired Immunodeficiency Syndrome). The disease degrades the immune system of the body over time, that is, breaks the mechanism of fighting body diseases. AIDS is currently in the category of incurable diseases. However, medicines can be taken to prolong the lives of patients. Developments such as this may be a breakthrough for treating AIDS.